Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Alternext  >  Cellectis    ALCLS   FR0010425595

CELLECTIS

(ALCLS)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Alternext
02/17/2020 02/18/2020 02/19/2020 02/20/2020 02/21/2020 Date
15.89(c) 15.77(c) 16.7(c) 17.29(c) 16.91(c) Last
23 141 58 067 74 801 87 208 52 261 Volume
-2.40% -0.76% +5.90% +3.53% -2.20% Change
More quotes
Financials (EUR)
Sales 2019 19,7 M
EBIT 2019 -108 M
Net income 2019 -95,2 M
Finance 2019 218 M
Yield 2019 -
Sales 2020 49,7 M
EBIT 2020 -121 M
Net income 2020 -110 M
Finance 2020 237 M
Yield 2020 -
P/E ratio 2019 -5,33x
P/E ratio 2020 -6,24x
EV / Sales2019 25,4x
EV / Sales2020 9,67x
Capitalization 718 M
More Financials
Company
Cellectis is developing the first of its kind allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients. As a clinical-stage biopharmaceutical company with over 20 years of expertise in gene... 
More about the company
Surperformance© ratings of Cellectis
Trading Rating : Investor Rating : -
More Ratings
Latest news on CELLECTIS
02/19CELLECTIS : and Servier Expand Collaboration on UCART19 Products; Cellectis : gr..
AQ
02/18CELLECTIS : and Servier Expand Collaboration on UCART19 Products
BU
02/05CALYXT, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
01/21CALYXT, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form..
AQ
01/16CELLECTIS : First Patient Dosed with Cellectis' New Allogeneic UCART123 Product ..
AQ
01/15CELLECTIS S A : First Patient Dosed with Cellectis' New Allogeneic UCART123 Prod..
BU
01/14Allogene Therapeutics and Spring Works Therapeutics Announce Clinical Collabo..
AQ
01/07CELLECTIS : and World Experts Review New Avenue of Allogeneic CAR T-cells, Optim..
AQ
01/07CELLECTIS : An Expert Review on Allogeneic CAR-T for Cancer Published in Nature ..
AQ
01/07CELLECTIS : An Expert Review on Allogeneic CAR-T for Cancer Published in Nature ..
AQ
01/06CELLECTIS :  An Expert Review on Allogeneic CAR-T for Cancer Published in Nature..
BU
2019CALYXT, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form..
AQ
2019CELLECTIS : 1st Patient Dosed with Cellectis' Allogeneic UCART22 in Relapsed/Ref..
AQ
2019CELLECTIS S A : 1st Patient Dosed with Cellectis' Allogeneic UCART22 in Relapsed..
BU
2019CELLECTIS : Wins Patent Challenge in Europe for a Method Using CRISPR-Cas9 for G..
BU
More news
News in other languages on CELLECTIS
02/19CELLECTIS : étend sa collaboration avec Servier
02/19STOCK MARKET PARIS : Apple, comme une lettre à la poste
02/19EN DIRECT DES MARCHES : EDF, Renault, Sanofi, Atos, Worldline, Tesla, Boeing...
02/18CELLECTIS : et Servier étendent leur collaboration sur les produits UCART19
01/16STOCK MARKET PARIS : Amis avec sursis
More news
Stock Trading Strategies
CELLECTIS - 2019
A technical turn-around configuration
BUY
More Stock Trading Analysis
Sector news : Biotechnology & Medical Research - NEC
02/20Anglo American Discloses All Mine Deaths in Industry Shift--Update
DJ
02/20Anglo American Discloses All Mine Deaths in Industry Shift -- Update
DJ
02/20Anglo American Discloses All Mine Deaths in Industry Shift
DJ
02/20GlaxoSmithKline Invests $50 Million in Biotech Startup's Cell-Therapy Program
DJ
02/19Five Prime Therapeutics In License Agreement with Seattle Genetics
DJ
More sector news : Biotechnology & Medical Research - NEC
Chart CELLECTIS
Duration : Period :
Cellectis Technical Analysis Chart | ALCLS | FR0010425595 | MarketScreener
Technical analysis trends CELLECTIS
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 25,05  €
Last Close Price 16,91  €
Spread / Highest target 50,8%
Spread / Average Target 48,1%
Spread / Lowest Target 45,5%
EPS Revisions
Managers
NameTitle
André Choulika Chairman & Chief Executive Officer
Elsy Boglioli Chief Operating Officer
Eric Dutang Chief Financial Officer
Philippe Duchateau Chief Scientific Officer
Stephane Depil Chief Medical Officer, EVP-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
CELLECTIS7.84%792
LONZA GROUP19.03%31 732
IQVIA HOLDINGS INC.5.77%31 649
SEATTLE GENETICS, INC.2.40%20 383
CELLTRION, INC.--.--%19 812
INCYTE CORPORATION-5.21%17 943